Loading...

Early TAVR And EVOQUE Launches Will Expand Access

Published
06 Aug 24
Updated
07 May 25
AnalystConsensusTarget's Fair Value
US$87.73
14.3% undervalued intrinsic discount
10 Sep
US$75.19
Loading
1Y
10.2%
7D
-1.9%

Author's Valuation

US$87.7314.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 9.47%

Shared on30 Apr 25
Fair value Decreased 0.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 0.43%

Shared on09 Apr 25
Fair value Increased 0.037%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.56%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.062%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 12%

AnalystConsensusTarget has increased revenue growth from 3.7% to 9.0%.